Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: Mol Cancer Ther. 2013 Oct 29;13(1):134–143. doi: 10.1158/1535-7163.MCT-13-0187

Table 2.

Tivantinib and Crizotinib inhibition (IC50) of p-MET and cell growth of cancer cells.

		Tivanitivib		Crizotinib
		p-MET inhibition (IC50)	Growth inhibition (IC50)	p-MET inhibition (IC50)	Growth inhibition (IC50)
MDA-MB-231	Report (5, 8)	0.1–0.3 μM	0.55 μM	0.011 μM	NA
MDA-MB-231	Test	> 1 μM	0.65 μM	0.01–0.1μM	2.8 μM
HT-29	Report (5, 8)	0.1–0.3 μM	0.49 μM	0.011 μM	NA
HT-29	Test	> 1 μM	0.54 μM	0.01–0.1μM	2.6 μM
SW1736	Test	≈ 1 μM	0.11 μM	0. 1–1μM	2.5 μM
TL3	Test	≈ 1 μM	0.33 μM	< 0.1μM	2.6μM

Note: IC50 values of p-MET inhibition in our tests were estimated according to the western blotting results. NA: not analyzed.